Plasma Exchange	Cytapheresis
Category I Standard and acceptable under certain circumstances, Including primary therapy
Coagulation factor inhibitors	Leukemia with hyperleukocytosis syndrome
Cryoglobulinemia	Sickle cell syndromes (also see Category II)
Goodpasture's syndrome	Thrombocytosis , symptomatic
Guillain-Barre syndrome
Homozygous familial hypercholesterolemia
Hyperviscosity syndrome
Myasthenia gravis
Posttransfusion purpura
Refsum's disease
Thrombotic thrombocytopenic purpura (TTP)
Category II Sufficient evidence to suggest efficacy ; acceptable therapy on an adjunctive basis
Chronic inflammatory demyelinating polyneuropathy	Cutaneous T-cell Lymphoma (cytoreduction or photopheresis)
Cold agglutinin disease
Drug overdose and poisoning (protein bound toxins)	Hairy cell leukemia
Hemolytic uremic syndrome (HUS)	Hyperparasitemia (e.g., malaria)
Pemphigus vularis	Peripheral blood stem cell collections for hematopoietic reconstitution
Rapidly progressive glomerulonephritis
Systemic Vasculitis (1o or 2 o RA or SLE)	Rheumatoid arthritis
Category III Inconclusive evidence for efficacy; uncertain benefit/risk ratio
ABO-incompatible organ or marrow transplantation	Life threatening hemolytic transfusion reactions Multiple sclerosis
Maternal treatment of maternal-fetal incompatibility (HDN)	Multiple sclerosis
Thyroid storm	Organ transplant rejection (also photopheresis)
Multiple sclerosis	Sickle cell disease (prophylactic use in pregnancy)
Progressive systemic sclerosis
Pure red cell aplasia
Transfusion refractoriness due to alloantibodies (red cell , platelet , HLA )
Warm autoimmune hemolytic anemia
Category IV Lack of efficancy in controlled trials
AIDS (for symptoms of immunodeficiency)	Leukemia with out hyperleukocytosis syndromes
Amyotrophic lateral sclerosis	Hypereosinophilia
Aplastic anemia	Polymyositis/dermatomyositis
Fulminant hepatic failure
ITP (chronic)
Lupus nephritis
Psoriasis
Renal transplant rejection
Rheumatoid arthritis
Schizophrenia